期刊
EUROPEAN JOURNAL OF ANAESTHESIOLOGY
卷 28, 期 1, 页码 3-6出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/EJA.0b013e32833e266d
关键词
anaesthesia; dexmedetomidine; extracellular signal-regulated kinases; focal adhesion kinase; ICU; sedation; sepsis; sleep
Dexmedetomidine is a potent alpha-2-adrenergic agonist, more selective than clonidine, with widespread actions on the mammalian brain that include sedation, anaesthetic-sparing, analgesia and sympatholytic properties. A large body of recent work supports its favourable profile in improving outcome and long-term brain function in the critically ill. The source of these benefits may lie in the neuroprotective properties that are seen in experimental models and in the clinical setting, in which it can attenuate delirium, preserve sleep architecture, preserve ventilatory drive and decrease sympathetic tone and inflammatory response. Dexmedetomidine may also be a valuable adjuvant when regional anaesthesia is used. Future research should aim at establishing the risk/benefit ratio when used at the bedside. Eur J Anaesthesiol 2011;28:3-6 Published online 27 September 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据